Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,546 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Girls, alone Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Study of Ovulation in Obese Women

NCT06306131
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 7:50 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Real-World Evidence Study Evaluating the Effects of the Human Optimization Project Protocol on Methylation Biomarkers and Health-Related Quality of Life in Women

NCT07548645
View directory record Official record
Conditions
Longevity, Women's Health
Interventions
Human Optimization Project
Dietary Supplement
Lead sponsor
Human Optimization Project
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers

NCT01303445
View directory record Official record
Conditions
Healthy
Interventions
Aggrenox alone, Aggrenox and omeprazole, Omeprazole alone
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 30, 2026, 7:50 AM EDT
Terminated Phase 2 Interventional Results available

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

NCT00372996
View directory record Official record
Conditions
Breast Neoplasms
Interventions
CP-751,871, exemestane, Fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
33
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 30, 2026, 7:50 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Lerociclib in Participants With Advanced Breast Cancer

NCT05085002
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Lerociclib + Letrozole or Fulvestrant
Drug
Lead sponsor
EQRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Jacksonville, Florida • Omaha, Nebraska • Salem, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DSM265 Prophylaxis of Plasmodium Falciparum Malaria

NCT02562872
View directory record Official record
Conditions
Healthy
Interventions
DSM265, Placebo, Sporozoites, Infective mosquito bite
Drug · Biological
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

NCT04978688
View directory record Official record
Conditions
Healthy
Interventions
Relugolix, E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Beetroot Supplementation in Women Enjoying Exercise Together

NCT04370756
View directory record Official record
Conditions
Aging, Postmenopause, Obesity
Interventions
Beetroot Juice, Exercise Training
Dietary Supplement · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 30, 2026, 7:50 AM EDT
Completed No phase listed Observational

Delphinus SoftVue™ ROC Reader Study

NCT03972605
View directory record Official record
Conditions
Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
Interventions
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 30, 2026, 7:50 AM EDT
Terminated Phase 4 Interventional

An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder

NCT05254405
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Brexanolone Injection [Zulresso]
Drug
Lead sponsor
Donald Jeffrey Newport
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)

NCT05309694
View directory record Official record
Conditions
Contraception
Interventions
Paragard® T380A Intrauterine Copper Contraceptive with New Inserter
Combination Product
Lead sponsor
CooperSurgical Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
8
States / cities
Denver, Colorado • South Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women

NCT00540878
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689 oral tablets (400 mg)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

NCT06310616
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Loestrin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer

NCT01654458
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological, Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female
Interventions
GyneGals Support Group
Behavioral
Lead sponsor
Women's College Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects

NCT01487239
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C]-GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

NCT01631201
View directory record Official record
Conditions
Chlamydia Trachomatis Infection
Interventions
Rifalazil 25 milligram, Azithromycin 1 gram
Drug
Lead sponsor
ActivBiotics Pharma, LLC
Industry
Eligibility
19 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Potential of Mavorixafor

NCT06914869
View directory record Official record
Conditions
Healthy Participants
Interventions
Mavorixafor, Carbamazepine, Efavirenz
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

NCT03443895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AEF0117 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects

NCT02747641
View directory record Official record
Conditions
Atrophy, Vaginal Atrophy, Genital Diseases, Female
Interventions
Pixel CO2 Laser System
Procedure
Lead sponsor
Alma Lasers Inc.
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 30, 2026, 7:50 AM EDT
Not listed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

NCT00012311
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CMF regimen, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, fluorouracil, ifosfamide, methotrexate, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 59 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 30, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing Adaptive Interventions to Improve Physical Activity for Sedentary Women

NCT03558828
View directory record Official record
Conditions
Physical Activity
Interventions
Step 1: PA Monitor, Step 1: PA Monitor + Text, Step 2: PA Monitor with Calls, Step 2: PA Monitor with Meetings, Step 2: PA Monitor + Texts with Calls, Step 2: PA Monitor + Texts with Meetings, Step 3: PA Monitor
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 30, 2026, 7:50 AM EDT
Completed No phase listed Observational

Indomethacin PK and PD Therapy in Pregnancy

NCT02451228
View directory record Official record
Conditions
Premature Labor, Pregnancy, Premature Birth
Interventions
Serial blood collection
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Birmingham, Alabama • Jackson, Mississippi • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 30, 2026, 7:50 AM EDT
Not listed Phase 2 Interventional

Brief Intervention to Reduce Drinking and Intimate Partner Violence in Women

NCT00539812
View directory record Official record
Conditions
Intimate Partner Violence, Substance Use
Interventions
Standard Care, Brief Alcohol Intervention combined with standard care
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 30, 2026, 7:50 AM EDT
Terminated Phase 2 Interventional

Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer

NCT04149522
View directory record Official record
Conditions
Breast Cancer, Radiotherapy; Adverse Effect, Dermatitis or Eczema, Radiotherapy Side Effect, Radiation Burn, Radiation Dermatitis, Radiotherapy; Complications
Interventions
Mepitel Film®
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Clairton, Pennsylvania • Monroeville, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 30, 2026, 7:50 AM EDT